The COVID-19 pandemic has highlighted vulnerabilities in the Pharma manufacturing supply chain and India’s over-reliance on China as a global ingredient producer of APIs. As we adjust our supply chains to the new normal, we need to ensure that we can create alternative supply arrangements without compromising on quality, reduce potential disruption, and boost our technology infrastructure to prepare for the future.

Through this webinar, get to explore the following areas:

• Challenges & opportunities post COVID-19
• India’s role in the pharma supply chain
• Implementing the “China-plus-one” policy
• Adapting Pharma’s supply chain to the new normal